Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Medium-Dose CoronaVac Booster Immunogenicity Trial
NCT05165966Phase 4Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of coronavac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Geometric Mean Titer of neutralizing antibodies (CZ02 strain) at 14 days. Started Oct 2021; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05165966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165966.